Whalesbook
GLP-1 drug market mein ek bada earthquake aa gaya hai! Semaglutide active pharmaceutical ingredient (API), jo Ozempic aur Wegovy jaisi blockbuster dawaiyon ka main ingredient hai, uska rate ekdum se collapse ho gaya hai. Yeh sab badhti production aur patent expiry ki wajah se hua hai, aur isse sirf drugs sasti hi nahi ho rahi, balki market mein zabardast competition bhi aa gaya hai aur supply chain ki vulnerabilities bhi saamne aa gayi hain.
API Prices Collapse Amidst Generic Surge
Jo Semaglutide API, Ozempic aur Wegovy jaisi dawaiyon ka main ingredient hai, uska price ab $90-$160 (synthetic versions) ya $50 (recombinant types) per gram tak aa gaya hai. Pehle yeh $900 tak bikta tha! Iska reason hai China mein production ka badhna aur cost cutting. Experts bol rahe hain ki aage aur 20-30% price decrease dekhne ko mil sakta hai.
March 20, 2026 ko Novo Nordisk ke semaglutide patents expire hone ke baad, India ki Sun Pharma, Dr Reddy's Laboratories, Natco Pharma, Zydus Lifesciences, aur Eris Lifesciences jaisi badi companies ne turant apne generic versions launch kar diye hain. Yeh generics original brands se 70-90% kam price par aa rahe hain. Natco Pharma ka ek vial $14 per month mein mil raha hai, aur Sun Pharma ke bhi competitive options hain. Ab lakhon log iss dawa ko afford kar payenge.
Market Competition Aur Company Valuations
Ab iska pressure sidha Novo Nordisk par aa raha hai, jo iss market ki leader hai. Company ka stock iss saal kaafi gira hai. Unka Price-to-Earnings (P/E) ratio bhi kam hokar around 10.35-11.5 ho gaya hai. Isliye, Novo Nordisk ne India mein Ozempic aur Wegovy ke prices 48% tak kam kar diye hain, jo April 1, 2026 se लागू ho gaya hai. Woh 'Plosbrio' aur 'Poviztra' jaise branded generics bhi launch karne ka soch rahe hain taaki market mein bane rahein.
Indian generic companies filhaal achhi position mein lag rahi hain. Natco Pharma ka P/E 11.82, Zydus Lifesciences ka 19.09, aur Dr Reddy's Laboratories ka 18.46 hai. Analysts Dr Reddy's par 'Buy' rating de rahe hain, jiska target price ₹1,500–1,600 ke aas paas hai. Sun Pharmaceutical Industries ka P/E 37.33 aur Eris Lifesciences ka sabse zyada 44.12 hai, jo indicate karta hai ki yeh growth stocks hain.
GLP-1 Market Growth Aur Risks
Overall GLP-1 market ki growth kaafi zabardast rehne wali hai. Aisa estimate hai ki 2035 tak yeh global market $385.4 billion tak pahunch jayega, matlab 15.1% CAGR se badhega. Oral drugs aur triple-agonist molecules is growth ko aur fuel karenge.
Par bhai, growth forecast ke bawajood risks bhi kam nahi hain. Novo Nordisk ka bahut zyada reliance Ozempic aur Wegovy par hai, isliye price wars aur market share loss ka risk hai. Global supply chain bhi ek bada issue hai. Hum bahut zyada China par nirbhar hain API ke liye. Koi bhi geopolitical tension ya trade issue prices badha sakta hai. Indian generic companies ke liye yeh ek badi weakness hai. Agar API prices kam bhi hain, toh bhi koi bhi gadbad unke profits ko affect kar sakti hai.
Outlook for GLP-1 Market
Aage jaakar GLP-1 market mein growth toh rahegi hi, kyunki diabetes aur obesity ke cases badh rahe hain aur naye drugs aa rahe hain. Lekin generics ki wajah se prices kam hi rahenge. Novo Nordisk ko naye drugs aur innovation par focus karna hoga apni position bachane ke liye. Generic companies ko price kam hone aur supply chain issues ke beech profit banana hai, aur patient demand puri karni hai.